Teva Pharmaceutical (TEVA) revised its financial forecast after low third-quarter sales


Teva Pharmaceutical (TEVA) announced its financial results on Thursday reporting low third-quarter sales and the company reduce its full-year revenue figures.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


Teva reported 58 cents per share income for the quarter ended September 30, 2020, which is in line with the analyst’s estimates. The earing remains flat over the year. The company sales declined by 2.8% and the company earned $3.98 billion in sales, which is way behind than the $4.06 billion estimates. After the announcement, Teva stock floored 6.5% to 8.61.

The sales of generic products climbed 2% to $928 million in North America, but generic product sales declined in Europe and international markets1% and 10% respectively year over year.

The revenue from the sales of Copaxone declined in all three geographies and it was declined most in the North America where it dipped to 13% to $236 million which is still $26 million higher than the analyst’s forecast.

But that beat forecasts by $26 million, SVB Leerink analyst Ami Fadia said in a note to clients. She retained her market perform rating on Teva stock.

Copaxone is facing tough competition due to generic copies but Teva said that Copaxone has ‘stabilized’ in the U.S.

Teva revised its sales figure for the year. Now Teva is looking to earn16.5 billion to $16.8 billion in sales, which is $150 million lower than previous guidance at the midpoint. Also, the earning per share has been revised and Teva expecting $2.40-$2.55 earnings per share whereas analysts’ estimates are $16.65 billion in sales and $2.48 per share.


Please enter your comment!
Please enter your name here